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Abstract: Chronic obstructive pulmonary disease is a common condition and a major cause 
of mortality. COPD is characterized by irreversible airﬂ  ow obstruction. The physiological 
abnormalities observed in COPD are due to a combination of emphysema and obliteration of 
the small airways in association with airway inﬂ  ammation. The predominant cells involved 
in this inflammatory response are CD8+ lymphocytes, neutrophils, and macrophages. 
Although eosinophilic airway inﬂ  ammation is usually considered a feature of asthma, it has 
been demonstrated in large and small airway tissue samples and in 20%–40% of induced 
sputum samples from patients with stable COPD. This airway eosinophilia is increased in 
exacerbations. Thus, modifying eosinophilic inﬂ  ammation may be a potential therapeutic target 
in COPD. Eosinophilic airway inﬂ  ammation is resistant to inhaled corticosteroid therapy, but 
does respond to systemic corticosteroid therapy, and the degree of response is related to the 
intensity of the eosinophilic inﬂ  ammation. In COPD, targeting treatment to normalize the sputum 
eosinophilia reduced the number of hospital admissions. Whether controlling eosinophilic 
inﬂ  ammation in COPD patients with an airway eosinophilia will modify disease progression 
and possibly alter mortality is unknown, but warrants further investigation.
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Introduction
Chronic obstructive pulmonary disease is a common condition predominantly 
caused by smoking. It is a major cause of mortality, and in 1999 there were 
approximately 30 000 deaths due to COPD in the UK. This represented 5.1% of all 
deaths (5.9% of all male deaths and 4.3% of all female deaths) (NICE 2004). COPD 
is the major cause of respiratory failure and is a common cause of chronic disability. 
In contrast to asthma, COPD is characterized by irreversible airﬂ  ow obstruction. 
The physiological abnormalities observed in COPD are due to a combination 
of emphysema and obliteration of the small airways. These two pathologies are 
distinct in that emphysema can occur without narrowing of the small airways, and 
vice versa, although the conditions usually coexist. Small airway narrowing is a 
consequence of inﬂ  ammation, increased airway muscle mass and ﬁ  brosis in the 
airway wall, and the accumulation of inﬂ  ammatory mucus exudates in the lumen. 
Subsequent increased airway wall thickness is associated with worsening disease 
severity as deﬁ  ned by the Global Initiative of Obstructive Lung Disease (GOLD) 
stage (Hogg et al 2004).
There is considerable interest in airway inﬂ  ammation in COPD. This interest has 
been fuelled by the desire to modify airway inﬂ  ammation in COPD in the anticipation 
that this will have an impact on lung function decline and exacerbations, which are 
the major determinants of the morbidity and mortality associated with this disease. 
Neutrophils, CD8+ T lymphocytes, and macrophages have been implicated in the 
disease pathogenesis of COPD, whereas, asthma is regarded as a Th2-mediated 
eosinophilic disease. Indeed, the presence of eosinophilic inﬂ  ammation is often viewed 
as a distinguishing feature between asthma and COPD.International Journal of COPD 2006:1(1) 40
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The development of sputum induction as a non-invasive 
test of airway inﬂ  ammation has enabled clinicians to 
study the phenotype of airway inﬂ  ammation in patients 
with airway disease. The sputum differential cell count 
has been defined in large normal populations (Belda 
et al 2000). The normal sputum eosinophil count 
is 1.1%. A sputum eosinophil count 3% was associ-
ated with a good response to corticosteroids in asthma 
(Pavord et al 1999) and COPD (Pizzichini et al 1998). 
The application of sputum induction has led to the 
recognition that eosinophilic inﬂ  ammation is present in 
only 50% of cases of asthma (Douwes et al 2002) and 
in about 20%–40% of cases of COPD (Saetta et al 1994; 
Confalonieri et al 1998; Pizzichini et al 1998; Brightling, 
Monteiro, et al 2000; Brightling et al 2005). Hence there 
is considerable overlap in the presence of eosinophilic 
airway inﬂ  ammation in COPD and asthma, as illustrated 
in Figure 1 (Brightling, Monteiro, et al 2000; Green, 
Brightling, Woltmann, et al 2002).
In this review we brieﬂ  y summarize eosinophil biology, 
describe the inflammatory profile of COPD in stable 
disease and exacerbations and its response to treatment 
with particular reference to the eosinophil, and explore the 
potential role of a sputum eosinophil count in the management 
of COPD.
Eosinophil biology
Eosinophils are end-stage cells derived from the bone 
marrow under the inﬂ  uence of granulocyte-macrophage 
colony-stimulating factor (GM-CSF), interleukin (IL)-3, 
and the late differentiation factor IL-5 (Denburg 1999). 
In terms of their ontogeny they are closely related to the 
basophil rather than the neutrophil or monocyte. The 
selective recruitment of eosinophils into the airway is 
mediated by a multistep process directed by Th2 cytokine-
producing T cells (Wardlaw et al 1999). The ﬁ  rst step is 
increased production and release of eosinophils from the 
bone marrow under the inﬂ  uence of the IL-5 and speciﬁ  c 
chemoattractants such as eotaxin. Second, the target organ 
vasculature has increased adhesiveness for eosinophils 
through the speciﬁ  c effects of locally generated IL-4 and 
IL-13. These cytokines induce expression of vascular cell 
adhesion molecule (VCAM)-1 on lung endothelial cells, 
which binds through eosinophil -expressed ligands VLA-4 
and P-selectin, to which eosinophils bind with greater 
avidity than neutrophils (Symon et al 1996; Edwards 
et al 2000; Woltmann et al 2000). CC chemokines such 
as eotaxin released by cells in the airway wall activate 
the chemokine receptor CCR3 expressed by eosinophils 
and thus attract these cells into tissue. Here they survive 
for prolonged periods as a result of locally generated IL-5 
and GM-CSF.
The eosinophil specific basic proteins, which are 
stored in the distinctive secondary granules, are major 
basic protein eosinophil cationic protein (ECP), eosinophil 
peroxidase (EPO), and eosinophil-derived neurotoxin. All 
of these proteins are toxic to bronchial epithelial cells. 
Eosinophils, with mast cells and basophils, are the most 
prominent source of cysteinyl-leukotrienes (Bozza et al 
1997), and eosinophils also release a diverse range of 
cytokines. The physiological triggers in airway disease 
that lead to eosinophil mediator release remain uncer-
tain but, importantly, eosinophils undergo piecemeal 
degranulation in most in vivo settings (Dvorak and 
Weller 2000).
Airway inﬂ  ammation in COPD
Stable disease
For more than a decade, substantial effort has been made 
to deﬁ  ne obstructive airways disease at an inﬂ  ammatory 
cellular level with the aim to clarify mechanisms and 
improve treatment. Sputum and bronchoalveolar lavage 
(BAL) have been used to identify inﬂ  ammatory components 
Figure 1 Sputum eosinophil count in subjects with corticosteroid-naïve 
asthma and COPD. Data derived from Brightling, Monteiro, et al (2000); Green, 
Brightling, Woltmann, et al (2002).
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of the large and small airways, respectively, whereas 
endobronchial biopsies and lung resection tissue have been 
used for analysis of the bronchial wall of the large and small 
airway and lung parenchyma. There are several difﬁ  culties 
facing researchers interested in measuring lower airway 
inﬂ  ammation in COPD. First, the functionally important 
inﬂ  ammatory response in the small airways and surrounding 
lung parenchyma is in the lung periphery and is therefore 
difﬁ  cult to access. Second, the various techniques used to 
assess airway inﬂ  ammation differ markedly in their proper-
ties and in the proﬁ  le of inﬂ  ammatory cells they measure, 
suggesting they are accessing different lung compartments 
(Keatings, Evans, et al 1997). Finally, when considering 
airway inﬂ  ammation, the repeatability of such measures is 
not always known.
Despite these problems, a number of inﬂ  ammatory 
cells have been shown consistently to be present in 
increased numbers in the airways in COPD and to relate 
to the severity of airﬂ  ow obstruction, suggesting a causal 
role. The evidence is perhaps strongest for the CD8+ 
T lymphocyte and the neutrophil. Increased numbers of 
CD8+ T lymphocytes have been demonstrated at all levels 
of the lung (large and small airways and parenchyma) in 
relation to smoking and COPD (O’Shaughnessy et al 1997; 
Saetta et al 1999). The mechanism of CD8+ lymphocyte 
recruitment and its functional signiﬁ  cance remain to be 
determined. Increased neutrophil numbers are particularly 
obvious in patients with established airflow obstruc-
tion. Bronchial biopsy and induced sputum studies have 
consistently shown a correlation between the severity of 
airﬂ  ow obstruction and neutrophil counts, and in some 
studies the correlation has been close (Keatings et al 1996; 
Stanescu et al 1996; Di Stefano et al 1998). Furthermore, 
the protease-antiprotease hypothesis (Stockley 1995) offers 
a biologically plausible mechanism for the tissue destruc-
tion seen in COPD in association with neutrophilic airway 
inﬂ  ammation.
Less attention has been paid to the presence of 
eosinophilic airway inﬂ  ammation in stable COPD, although 
a sputum eosinophilia has been observed in 20%–40% 
of patients with COPD (Saetta et al 1994; Confalonieri 
et al 1998; Pizzichini et al 1998; Brightling, Monteiro, et al 
2000; Brightling et al 2005). One bronchial biopsy study has 
reported an increased number of eosinophils in patients with 
chronic bronchitis and COPD but lower BAL concentrations 
of ECP than in asthmatics, suggesting that eosinophils are 
present but are less activated in COPD (Lacoste et al 1993). 
However, sputum ECP concentrations were increased to a 
greater level than seen with asthma in moderate to severe 
COPD (Gibson et al 1998; Brightling, Monteiro, et al 
2000; Brightling, Ward, et al 2000; Brightling et al 2005), 
suggesting that eosinophils are activated in more severe 
disease.
The relationship between lung function decline and 
eosinophilic inﬂ  ammation is unclear. A negative correlation 
between FEV1 and the ratio of activated eosinophils to total 
eosinophils in endobronchial biopsies from subjects with 
COPD was demonstrated (Lams et al 2000), and a similar 
negative correlation between FEV1 and sputum eosinophils 
and ECP was found (Balzano et al 1999). Conversely, in 
another study there was no relationship between small airway 
eosinophilia and severity of COPD deﬁ  ned by the GOLD 
criteria (Hogg et al 2004).
The origin of eosinophilic airway inﬂ  ammation in COPD 
is unclear, although it is widely assumed that it indicates 
an asthmatic component to the ﬁ  xed airways obstruction 
(Barnes 1998). This is unlikely to be the case, as most 
studies on patients with COPD rigorously exclude subjects 
with variable airﬂ  ow obstruction and those with clinical 
features suggesting asthma. It is more likely that smoking 
and other mechanisms that recruit neutrophils into the 
airway mucosa in COPD may in turn cause a minor degree 
of eosinophil inﬂ  ux. However, it is difﬁ  cult to explain the 
very high levels of sputum eosinophilia observed in some 
of our subjects. An alternative and intriguing possibility is 
that eosinophilic COPD starts as eosinophilic bronchitis. 
This is a common cause of chronic cough in middle age 
characterized by a sputum eosinophilia but no symptoms 
and functional evidence of variable airﬂ  ow obstruction or 
airway hyperresponsiveness (Gibson et al 1989). Although 
characterized by normal spirometric values at the time of 
diagnosis, this has been associated with an accelerated 
decline in FEV1 and the development of COPD (Brightling 
et al 1999; Birring et al 2002; Berry et al 2005).
Exacerbations
COPD exacerbations are associated with sputum and 
bronchoscopic bronchial biopsy evidence of eosinophilic 
inflammation (Lacoste et al 1993; Saetta et al 1994). 
Bronchial biopsies taken from patients during acute 
exacerbations and compared with stable COPD show a 
30-fold increase in the total number of eosinophils and 
only a 3-fold increase in neutrophils (Saetta et al 1994). 
The presence of high concentrations of tumor necrosis 
factor (TNF)-α (a proinﬂ  ammatory cytokine that activates 
adhesion molecules on endothelial cells influencing International Journal of COPD 2006:1(1) 42
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eosinophil chemotaxis) and the eosinophil products ECP 
and EPO in induced sputum also supports a role for the 
eosinophil in COPD exacerbations (Pizzichini et al 1996; 
Gursel et al 1997; Keatings and Barnes 1997; Keatings, 
Evans, et al 1997).
Effect of treatment on airway 
inﬂ  ammation
Intervention studies examining the effects of treatment 
on airway inflammation in COPD have generally used 
induced sputum to assess airway inflammation and 
inhaled or oral corticosteroids as the putative antiin-
flammatory agent. These studies are summarized in 
Table 1.
There is a consistent lack of effect on eosinophilic 
inflammation in COPD by inhaled corticosteroids 
(Keatings, Jatakanon, et al 1997; Confalonieri et al 1998; 
Culpitt et al 1999; Loppow et al 2001; Gizycki et al 2002; 
Brightling et al 2005). Two studies have shown a small 
reduction in the sputum neutrophil count (Confalonieri 
et al 1998; Yildiz et al 2000) and one a reduction in 
submucosal mast cell numbers (Gizycki et al 2002). The 
lack of an antiinﬂ  ammatory effect of inhaled corticosteroid 
therapy in COPD has led to the hypothesis that COPD is 
a corticosteroid-resistant disease. Low levels of histone 
deacetylase (HDAC) demonstrated in COPD macrophages 
and lung tissue may be responsible for corticosteroid 
resistance (Ito et al 2005). HDAC prevents acetylation of 
histone, which leads to unwinding of chromatin architec-
ture, thereby promoting transcription of proinﬂ  ammatory 
cytokines implicated in COPD. Reduced levels of HDAC 
in macrophages have been seen in response to cigarette 
smoke. Levels are negatively correlated with increased 
levels of metalloproteinases, IL-8, and TNFα and a 
reduction in the ability of dexamethasone to reduce these 
mediators (Barnes et al 2004). However, though studies 
show that COPD is relatively corticosteroid resistant 
compared with asthma, the response of airway inﬂ  am-
mation in COPD to systemic corticosteroids suggests 
that certain aspects of the inflammatory profile in 
COPD are corticosteroid responsive (Table 1).
One small single-blind study has shown that following 
treatment with a short course of prednisolone there was no 
evidence of a treatment-associated change in the sputum 
neutrophil count or in the sputum supernatant concentra-
tion of myeloperoxidase or elastase (Pizzichini et al 1998). 
The authors observed that oral corticosteroid treatment is 
associated with a signiﬁ  cant fall in the sputum eosinophil 
count and in the sputum supernatant concentration of ECP. 
Furthermore, the improvement in FEV1 and quality-of-life 
scores with treatment was signiﬁ  cantly greater in those with 
a signiﬁ  cant sputum eosinophilia (3%) (Pizzichini et al 
1998). This beneﬁ  cial effect of oral corticosteroid treatment 
was conﬁ  rmed in a randomized placebo-controlled trial of 
2 weeks of prednisolone 30 mg daily. This study found 
that the degree of baseline eosinophilic inﬂ  ammation was 
related to improvements in lung function and health status 
(Figure 2) (Brightling, Monteiro, et al 2000). Fujimoto 
et al (1999) treated 24 emphysema subjects (deﬁ  ned by 
obstructive spirometry with demonstrable irreversibility 
and emphysema on CT scan) with oral prednisolone 20 mg 
daily for 2 weeks with analysis of sputum before and after 
treatment. Corticosteroids did not modulate neutrophilic 
inﬂ  ammation, but reduction in eosinophils was observed, 
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Figure 2 Improvement in post-bronchodilator FEV1, health status (Chronic Respiratory Disease Questionnaire; CRQ), and shuttle walk distance in subjects with 
COPD with or without a sputum eosinophilia (3% non-squamous cells). *p  0.05; Δ represents change after prednisolone compared with placebo. Data derived from 
Brightling, Monteiro, et al (2000).International Journal of COPD 2006:1(1) 43
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Table 1 Studies monitoring effect of corticosteroids (inhaled and oral) on airway inﬂ  ammation and lung function
Reference
Number of 
patients Design of trial
Severity of 
COPD Inﬂ  ammatory cell outcome
Lung function 
outcome
Barnes et al 2005 
Qui et al 2005 
Zhu et al 2005
140 Randomized, double-blind; 
12 weeks of inhaled 
combined salmeterol/
ﬂ  uticasone therapy
FEV1 59% Reduction in sputum neutrophils 
and eosinophils and nonsigniﬁ  cant 
reduction in submucosal mast 
cells from EBB.   Also reduction 
in TNFα and IFNγ +ve cells in 
subepithelium
Increase in FEV1 
(0.17 L) in treatment 
group. Reduction 
in exacerbations 
(treatment 16% vs 
33% placebo)
Brightling et al 2005 60 Randomized, double-blind, 
crossover; 6 weeks of 
inhaled mometasone or 
placebo 800 μg daily
FEV144% No change in sputum cell counts No signiﬁ  cant 
overall increase. Post 
BD FEV1 increase 
improved with 
increasing tertile of 
sputum eosinophil 
count
Gizycki et al 2002 24 Randomized, double-blind; 
3 months of ﬂ  uticasone 
1000 μg daily
FEV150% No change in inﬂ  ammatory cells 
in EBB except for submucosal 
mast cells. Increase in neutrophils 
in EBB
No change in 
lung function
Hattotuwa et al 2002 30 Randomized, double-blind; 
3 months of ﬂ  uticasone 
1000 μg daily
FEV145% No signiﬁ  cant change in CD8+, 
macrophages, neutrophils, and 
eosinophils in EBB. Reduction in 
submucosal mast cells
No change in 
lung function
Loppow et al 2001 19 Randomized, double-blind, 
crossover; 4 weeks of 
ﬂ  uticasone or placebo 
1000 μg daily in chronic 
bronchitis ± mild 
obstruction
FEV1 83% 
FEV1/VC 68%
Decrease in total number of cells 
in sputum in ﬂ  uticasone group 
but not when compared against 
placebo. No change in differen-
tial counts, IL-8, ECP, and NPE. 
No change in lung function and 
exhaled NO
No change in 
lung function
Balbi et al 2000 8 Open clinical study; 
6 weeks of inhaled BDP 
1.5 mg daily
FEV170% Reduction in IL-8, MPO, total cell 
numbers, neutrophils (59.7% vs 
31.5% mean) in BAL
No change in 
lung function
Yildiz et al 2000 18 Randomized, double-blind; 
1500μg ﬂ  uticasone, in 
subgroup theophylline 
also added (not stated to 
which patients)
FEV142% Reduction in total cell count 
and neutrophils with ﬂ  uticasone 
with increase of neutrophils after 
washout period; no change in 
eosinophil count
No change in 
lung function
Culpitt et al 1999 13 Randomized, double-blind, 
crossover; 4 weeks of 
ﬂ  uticasone or placebo 
1000 μg daily
FEV1 50% No change in sputum cell counts 
or IL-8, MMP-1, -9, SLPI, and 
TIMP-1.
No clinical beneﬁ  t 
with lung function or 
symptom scores
Confalonieri et al
1998
34 Randomized, double-blind: 
2 months of BDP 1500 
μg daily
FEV1 60% Reduction of total cell count and 
neutrophils in sputum (−42% and 
−27%, respectively). No change in 
eosinophils
No change in lung 
function
Keatings, Jatakanon, 
et al 1997
13 Open study with 2 
weeks of budesonide 
1600 μg with analysis of 
induced sputum followed 
by 2-week course of 
prednisolone 30 mg daily, 
compared against 10 
atopic asthma subjects
FEV1 35% No reduction in ECP, EPO, MPO, 
TNFα, and IL-8 in sputum with 
inhaled corticosteroids Sputum 
eosinophil numbers, ECP, 
EPO reduced in asthma but not 
in COPD subjects with oral 
prednisolone
No change in lung 
functionInternational Journal of COPD 2006:1(1) 44
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Table 1 continued
Reference
Number of 
patients Design of trial
Severity of 
COPD Inﬂ  ammatory cell outcome
Lung function 
outcome
Brightling, Monteiro, 
et al 2000
67 Randomized, double-blind, 
crossover; 2 weeks of 
prednisolone 30 mg daily
FEV142% Reduction in sputum eosinophil 
counts
No signiﬁ  cant 
overall increase. Post 
BD FEV1 increase 
improved with 
increasing tertile of 
sputum eosinophil 
count. Increase in 
CRQ score
Fujimoto et al 1999 24 Open study of 2 weeks 
with prednisolone 20 mg 
daily
FEV141% Sputum measurements of cell 
counts, ECP, NPE-PI complex,and 
IL-8. Reduction in ECP and 
eosinophils
Baseline eosinophil 
count correlated 
with post-treatment 
FEV1 increase
Pizzichini et al 1998 18 Randomized, double-
blind; 2 weeks of oral 
prednisolone 30 mg daily
FEV1 29% Reduction in sputum eosinophil 
and ECP count
Eosinophilia 
indicated reduction 
in dyspnea and small 
increase in FEV1 
of 0.1 1 L
Chanez et al 1997 25 Open study with 15 days 
of prednisolone 1.5 mg/kg 
daily; eosinophilic inﬂ  am-
mation characterized by 
peripheral blood, BAL, 
and EBB
FEV1 51% Increased levels of eosinophils 
and ECP in BAL seen in steroid 
responders
12/25 subjects 
showed increase 
of FEV1 12% and 
200 mL
Abbreviations: BAL, bronchoalveolar lavage; BD, bronchodilator; BDP, beclomethasone dipropionate; CRQ, Chronic Respiratory Disease Questionnaire; EBB,
endobronchial biopsies; ECP, eosinophil cationic protein; EPO, eosinophil peroxidase; IFN, interferon; IL, interleukin; MMP, matrix metalloproteinase; MPO, 
myeloperoxidase; NPE, neutrophil elastase; NPE PI, neutrophil elastase-α-protease inhibitor; NO, nitric oxide; SLPI, secretory leukocyte proteinase inhibitor; TIMP, 
tissue inhibitor of metalloproteinase; TNF, tumor necrosis factor.
as were predicted improvements in FEV1. In another study, 
administration of 15 days of prednisolone (1.5 mg/kg daily) 
to 25 COPD subjects showed FEV1 improvements greater 
than 12% and 200 mL above baseline in 12 subjects; this 
subgroup exhibited raised levels of eosinophilic inﬂ  am-
mation in BAL specimens compared with nonresponders 
(Chanez et al 1997). Hence, reversibility can be predicted 
from evidence of tissue eosinophilia at baseline. Recently, 
a large placebo-controlled study using combination inhaler 
therapy (ﬂ  uticasone and salmeterol) has shown reduction in 
sputum eosinophils and neutrophils over a 12-week period 
when compared with placebo, with an associated improve-
ment in lung function and reported exacerbations (Barnes 
et al 2005; Qui et al 2005; Zhu et al 2005). Comparison 
between combination and single-agent inhaled therapy is 
required to clarify the antiinﬂ  ammatory beneﬁ  t of combined 
corticosteroid and long-acting β-agonists in COPD.
These observations suggest that systemic and inhaled 
corticosteroids have differential effects on airway inﬂ  am-
mation in COPD. The differences between the effects of 
oral versus inhaled corticosteroids may reﬂ  ect differences in 
dose or perhaps the site of action. Systemic corticosteroids 
are likely to exert more of an effect on small airway inﬂ  am-
mation, which is less accessible to inhaled therapy, and 
systemic corticosteroids also suppress eosinophil production 
by the bone marrow.
Sputum inﬂ  ammatory cell counts can be inﬂ  uenced to 
some extent by smoking status. A cross-sectional study 
showed COPD subjects who had given up smoking by 
12 months had a lower percentage of eosinophils than 
smokers, though sputum eosinophil levels were still high in 
both groups (smokers 8% vs 4% ex-smokers) (Domagala-
Kulawik et al 2003). There was no difference in the response 
to oral corticosteroids between current smokers and ex-
smokers (Brightling, Monteiro, et al 2000). These ﬁ  ndings 
are in contrast to those in smokers with asthma, who have 
reduced sputum eosinophil counts compared with non-
smokers and were less corticosteroid responsive (Chalmers 
et al 2001; Tomlinson et al 2005).
There has been little exploration into the effects of other 
antiinﬂ  ammatory treatments on COPD-related airway inﬂ  am-
mation. Cilomilast, an oral phosphodiesterase D4 inhibitor, International Journal of COPD 2006:1(1) 45
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has been used in a randomized, double-blind 12-week trial; 
there was no demonstrable difference in sputum counts or 
FEV1 after 12 weeks, but bronchial biopsies at 10 weeks 
showed reductions in macrophages and CD8+ T lymphocytes 
compared with baseline in the cilomilast treatment arm 
(Gamble et al 2003).
Role of measuring inﬂ  ammation in 
management of disease
One important question is whether measuring airway 
inﬂ  ammation in COPD can inﬂ  uence the management of 
this disease. This is particularly difﬁ  cult in a disease that is 
largely resistant to current therapy.
Several recent large, placebo-controlled studies have 
clarified the role of long-term treatment with inhaled 
corticosteroids. Regular treatment with inhaled corticoste-
roids in stable COPD does not alter the long-term decline 
in lung function (Pauwels et al 1999; Vestbo et al 1999; 
Burge et al 2000; The Lung Health Study Research Group 
2000), and there is conﬂ  icting evidence whether inhaled 
corticosteroids alter mortality (Soriano et al 2002; Fan et al 
2003). However, they do reduce the number of exacerbations 
and improve health status in individuals with severe COPD 
(Burge et al 2000; Mahler et al 2002; Jones et al 2003; 
Szafranski et al 2003). Intriguingly, subjects who had an 
improvement in FEV1 of 20% following short-term 
treatment with prednisolone had a more signiﬁ  cant reduc-
tion in exacerbation frequency with longer-term treatment 
with inhaled ﬂ  uticasone than those without (Burge et al 
2003; Pavord et al 2004). This suggests that the beneﬁ  t from 
corticosteroid therapy in COPD is more marked in a subgroup 
of patients. Likewise in an earlier uncontrolled study, COPD 
subjects treated with oral corticosteroids had reduced decline 
in their lung function (Postma et al 1988). Thus, one impor-
tant question is whether these relatively minor long-term 
beneﬁ  ts are conﬁ  ned to a deﬁ  nable subgroup of patients.
Since sputum eosinophilia was also associated with 
an improvement in lung function after a short course of 
prednisolone, it is possible that the identiﬁ  cation of eosino-
philic airway inﬂ  ammation might still allow corticosteroid 
therapy to be targeted to a population who would particu-
larly beneﬁ  t in the long term, in terms of both exacerbation 
rate and lung function decline. This approach has been 
applied to asthma, whereby in a management strategy 
aimed at normalizing the sputum eosinophil count there 
was a striking reduction in severe exacerbations (Green, 
Brightling, McKenna, et al 2002). We have recently 
applied this approach to a group of 80 subjects with COPD. 
Over a 12-month period, we have shown that a management 
approach with the additional aim of reducing the sputum 
eosinophil count below 3% using corticosteroids was associ-
ated with a 62% reduction in severe exacerbations of COPD 
requiring hospitalization when compared with traditional 
symptom-based management (Siva et al 2005). This beneﬁ  t 
was largely achieved by the targeted use of oral corticoste-
roid in the eosinophilic group. Therefore, the measurement 
of a sputum eosinophil count can be used to identify COPD 
patients with corticosteroid-responsive disease and to guide 
treatment.
Future treatments for eosinophilic 
inﬂ  ammation
COPD therapies have limited efﬁ  cacy. It is likely that iden-
tiﬁ  cation of speciﬁ  c inﬂ  ammatory phenotypes may reveal 
subgroups of patients who are particularly susceptible to 
targeted therapy. New treatments speciﬁ  cally aimed at modi-
fying eosinophilic inﬂ  ammation may have beneﬁ  t in some 
patients with COPD. The best documented of these is mepo-
lizumab, an anti-IL-5 antibody. In clinical trials, reduction of 
peripheral blood and bone marrow eosinophils was seen after 
administration but with little clinical beneﬁ  t observed. This 
was possibly due to poor penetration of bronchial tissue, the 
site of activity for eosinophils in asthma (Flood-Page et al 
2003). In murine models, overexpression of IL-13 leads to 
pulmonary emphysema; potentially, treatment against IL-13 
may have therapeutic beneﬁ  t, though overall IL-13 levels in 
human emphysematous tissue are low (Boutten et al 2004). 
A neutralizing antibody against eotaxin (which promotes 
eosinophil recruitment as well) has reduced lung eosino-
philia in mice (Gonzalo et al 1996), and early clinical trials 
are ongoing with antibodies against receptor CCR3 on the 
eosinophil cell surface (Erin et al 2002). Whether these new 
therapies will be effective in COPD is unknown, and further 
clinical trials are required.
Summary
The mechanistic pathways behind airway inﬂ  ammation in 
COPD are complex, and clearly there is no one inﬂ  ammatory 
cell that is responsible for the spectrum of this disease. 
However, the argument is strong for a specific role of 
eosinophilic inﬂ  ammation in COPD. Eosinophilic airway 
inﬂ  ammation is linked to exacerbations, which contribute to 
both lung function and health decline. Airway eosinophilia 
is not evident in all COPD patients but a large subgroup 
can be clearly deﬁ  ned by simple, non-invasive sampling of 
sputum. This subgroup exhibits improvement in lung function International Journal of COPD 2006:1(1) 46
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and health status to systemic, but not inhaled corticosteroids.
Speciﬁ  c targeting of eosinophilic inﬂ  ammation may be 
effective in some patients with COPD, and validation of 
long-term systemic corticosteroids and new treatment regi-
mens is warranted in COPD patients who exhibit an airway 
eosinophilia.
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